Epigenetic dysregulation of ACE2 and interferon-regulated genes might suggest increased COVID-19 susceptibility and severity in lupus patients.
Angiotensin-Converting Enzyme 2
Betacoronavirus
/ immunology
CD11a Antigen
/ genetics
COVID-19
Coronavirus Infections
/ complications
Cytokines
/ genetics
DNA Methylation
Disease Progression
Epigenesis, Genetic
Genetic Predisposition to Disease
Host-Pathogen Interactions
/ genetics
Humans
Interferon Regulatory Factors
/ genetics
Lupus Erythematosus, Systemic
/ complications
NF-kappa B
/ genetics
Oxidative Stress
/ genetics
Pandemics
Peptidyl-Dipeptidase A
/ genetics
Pneumonia, Viral
/ complications
Protein Binding
Receptors, KIR
/ genetics
SARS-CoV-2
Signal Transduction
Spike Glycoprotein, Coronavirus
/ genetics
Viremia
/ complications
ACE2
COVID-19
Epigenetics
Interferon
Lupus
Methylation
SARS-CoV-2
Journal
Clinical immunology (Orlando, Fla.)
ISSN: 1521-7035
Titre abrégé: Clin Immunol
Pays: United States
ID NLM: 100883537
Informations de publication
Date de publication:
06 2020
06 2020
Historique:
received:
01
04
2020
revised:
04
04
2020
accepted:
04
04
2020
pubmed:
11
4
2020
medline:
24
6
2020
entrez:
11
4
2020
Statut:
ppublish
Résumé
Infection caused by SARS-CoV-2 can result in severe respiratory complications and death. Patients with a compromised immune system are expected to be more susceptible to a severe disease course. In this report we suggest that patients with systemic lupus erythematous might be especially prone to severe COVID-19 independent of their immunosuppressed state from lupus treatment. Specifically, we provide evidence in lupus to suggest hypomethylation and overexpression of ACE2, which is located on the X chromosome and encodes a functional receptor for the SARS-CoV-2 spike glycoprotein. Oxidative stress induced by viral infections exacerbates the DNA methylation defect in lupus, possibly resulting in further ACE2 hypomethylation and enhanced viremia. In addition, demethylation of interferon-regulated genes, NFκB, and key cytokine genes in lupus patients might exacerbate the immune response to SARS-CoV-2 and increase the likelihood of cytokine storm. These arguments suggest that inherent epigenetic dysregulation in lupus might facilitate viral entry, viremia, and an excessive immune response to SARS-CoV-2. Further, maintaining disease remission in lupus patients is critical to prevent a vicious cycle of demethylation and increased oxidative stress, which will exacerbate susceptibility to SARS-CoV-2 infection during the current pandemic. Epigenetic control of the ACE2 gene might be a target for prevention and therapy in COVID-19.
Identifiants
pubmed: 32276140
pii: S1521-6616(20)30239-4
doi: 10.1016/j.clim.2020.108410
pmc: PMC7139239
pii:
doi:
Substances chimiques
CD11a Antigen
0
Cytokines
0
Interferon Regulatory Factors
0
NF-kappa B
0
Receptors, KIR
0
Spike Glycoprotein, Coronavirus
0
spike protein, SARS-CoV-2
0
Peptidyl-Dipeptidase A
EC 3.4.15.1
ACE2 protein, human
EC 3.4.17.23
Angiotensin-Converting Enzyme 2
EC 3.4.17.23
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
108410Subventions
Organisme : NIAID NIH HHS
ID : R01 AI097134
Pays : United States
Organisme : NIAID NIH HHS
ID : U19 AI110502
Pays : United States
Commentaires et corrections
Type : UpdateOf
Informations de copyright
Copyright © 2020 Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest None of the authors has any financial conflict of interest to disclose.
Références
J Immunol. 2007 Oct 15;179(8):5553-63
pubmed: 17911642
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
J Exp Med. 2005 Aug 1;202(3):415-24
pubmed: 16043521
J Autoimmun. 2018 Jan;86:19-28
pubmed: 29066026
Clin Immunol. 2015 Jan;156(1):19-27
pubmed: 25451162
Arthritis Rheumatol. 2016 Sep;68(9):2200-9
pubmed: 27111767
J Autoimmun. 2014 Nov;54:127-36
pubmed: 25091625
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Cell. 2020 Apr 16;181(2):271-280.e8
pubmed: 32142651
Front Immunol. 2018 Apr 24;9:875
pubmed: 29740453
Arthritis Rheumatol. 2014 Jun;66(6):1574-82
pubmed: 24577881
J Autoimmun. 2013 Jun;43:78-84
pubmed: 23623029
Nat Rev Rheumatol. 2013 Nov;9(11):674-86
pubmed: 24100461
J Immunol. 2007 Nov 1;179(9):6352-8
pubmed: 17947713
Cell Rep. 2020 Jan 7;30(1):112-123.e4
pubmed: 31914379
Curr Rheumatol Rep. 2017 Jun;19(6):32
pubmed: 28470479
J Autoimmun. 2015 Apr;58:59-66
pubmed: 25638528
J Autoimmun. 2009 Aug;33(1):31-4
pubmed: 19464849
Am J Pathol. 2007 Apr;170(4):1136-47
pubmed: 17392154
Ann Rheum Dis. 2018 May;77(5):736-743
pubmed: 29437559
Lupus Sci Med. 2016 Apr 04;3(1):e000147
pubmed: 27099767
J Immunol. 2008 Dec 15;181(12):8761-6
pubmed: 19050297